Mergers and Acquisitions


Our Approach

Mergers and acquisitions (M&A) serve as an integral tool for BD in advancing its strategy of improving patient outcomes, reducing the cost of care, expanding access and enhancing the operations of our customers around the world. In recent years BD has completed dozens of tuck-in acquisitions including Parata Systems, Venclose, and Tepha we continue to seek out attractive opportunities which align with the strategies of BD’s businesses and regions.

BD has developed leading capabilities in transactional structuring, execution, due diligence and integration. BD's Corporate Development team partners with our businesses, functions and regions to evaluate potential opportunities. All M&A opportunities should be directed to our Corporate Development team based out of our global headquarters in Franklin Lakes, New Jersey, USA through the website submission form below.



“At BD, we employ an extremely disciplined approach to M&A through strong deal execution and integration capabilities which we have built over many years. We remain committed to our focus on expansion into high-growth adjacent markets by utilising M&A as a tool to drive value creation and continued durable growth.” 

Tom Polen, CEO

M&A Objectives

BD seeks inorganic opportunities that advance our long-term strategy through increasing patient access, driving better outcomes, managing system cost pressures, and improving health care safety. Directional criteria is provided below:

  • Differentiated technologies
  • Attractive underlying market growth
  • Global reach and application
  • Digital and connected devices / solutions
  • Medication management
  • Infectious disease diagnostics
  • Vascular access management
  • Chronic disease management (diabetes, PAD, ESRD)
  • Surgical procedures and urological disorders
  • Immunology research and testing